Loading clinical trials...

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDPhase 3NCT00811174

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

Octagam is a human normal immunoglobulin (IGIV) solution for intravenous administration. Octagam 5% is currently registered in more than 60 countries. This study will evaluate the efficacy, safety and...

Lead sponsor: Octapharma•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETEDNA

Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine

NCT04798677 · Immunity, Vaccine Reaction, and more

UNKNOWN

Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients

NCT03920735 · Hematologic Disease, Neoplams, and more

COMPLETEDNA

Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru

NCT02630082 · HIV Infections, Acquired Immunodeficiency Syndrome, and more

COMPLETEDNA

Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans

NCT01727895 · Immunologic Deficiency Syndromes

TERMINATEDNA

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00006054 · Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 14, 2017Terms

Trial snapshot

StatusTERMINATED

PhasePHASE3

Enrollment5

Start dateJan 2009

Last updatedJul 14, 2017

Condition

Immunologic Deficiency Syndromes

Locations shown

Contact Barbara Pyringer at Octapharma/ Vienna/ Austria for information

Vienna

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 14, 2017Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine

Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients

Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru

Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

Trial snapshot

Condition

Locations shown

For caregivers